MISSISSAUGA, ON, April 21, 2021 /PRNewswire/ - Nuvo
Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo
Healthcare ("Miravo" or "the Company") a Canadian focused
healthcare company with global reach and a diversified portfolio of
commercial products, today announced that it has filed and obtained
a receipt for a final base shelf prospectus with the securities
regulatory authorities in each of the provinces of Canada (the "Prospectus"). The Company has
filed the Prospectus to maintain financial flexibility and to have
the ability to offer the securities on an accelerated basis
pursuant to the filing of prospectus supplements. There is no
certainty any securities will be offered or sold under the final
short form base shelf prospectus.
The Prospectus is valid for a 25-month period, during which time
the Company may offer and issue, from time to time, common shares,
preferred shares, debt securities, warrants and subscription
receipts, or any combination thereof, having an aggregate offering
price of up to C$40,000,000. Any
issue of securities under the shelf prospectus will require the
filing of a prospectus supplement that will include the specific
terms of the securities being offered.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful. This news release does not constitute an
offer to sell or the solicitation of an offer to buy in
the United States and the
securities referred to in this news release may not be offered or
sold in the United States absent
registration under the U.S. Securities Act of 1933 or pursuant to
an applicable exemption from the registration requirements under
the U.S. Securities Act of 1933 and applicable state securities
laws.
About Miravo
Healthcare
Miravo is a Canadian focused, healthcare company with global
reach and a diversified portfolio of commercial products. The
Company's products target several therapeutic areas, including
pain, allergy, neurology and dermatology. The Company's
strategy is to in-license and acquire growth-oriented,
complementary products for Canadian and international
markets. Miravo's head office is located in Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The
Varennes facility operates in a
Good Manufacturing Practices (GMP) environment respecting the U.S.,
Canada and E.U. GMP regulations
and is regularly inspected by Health Canada and the U.S. Food and
Drug Administration. For additional information, please visit
www.miravohealthcare.com.
Forward-Looking Statements
This press release
contains forward-looking statements which reflect the Company's
current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/miravo-healthcare-files-final-base-shelf-prospectus-301274263.html
SOURCE Nuvo Pharmaceuticals Inc.